Normal colon iteratively stained with over 30 CST antibodies using the Cell DIVE multiplexed imaging solution. Biomarkers displayed CD8A (orange); CD11B (mauve); CD68 (magenta); CD79A(red); GZMB (green); PanCK (emerald); CD45 (aqua).
Leica Microsystems and Cell Signaling Technology (CST) have announced a partnership to validate CST antibodies on Leica Microsystems’ Cell DIVE multiplexed imaging solution. As an open multiplexing system, Cell DIVE offers flexibility in antibody selection, allowing researchers to design custom antibody biomarker panels. More than 30 CST antibodies have now been tested and verified using the Cell DIVE multiplexing workflow, giving researchers the ability to move forward with confidence.
“By using validated antibodies with Cell DIVE, our open multiplexed imaging solution, researchers gain back precious time to focus on their scientific work,” said James O’Brien, vice president of life sciences at Leica Microsystems. “Instead of spending time validating antibodies, the pre-validated antibodies from CST allow them to design their individual panels and obtain accurate and reproducible data quickly.”
The Cell DIVE interactive staining workflow enables the visualization of more than 60 biomarkers on a single sample. Coupled with images of whole tissue sections at the single-cell level, Cell DIVE provides spatial insights to deepen scientists’ understanding of the tissue microenvironment in key fields such as cancer research.
CST has a broad portfolio of antibodies, validated for immunohistochemistry (IHC) using a rigorous approach to ensure sensitivity and specificity, to detect key proteins in a variety of disease states. With this partnership, Leica Microsystems has tested CST antibodies conjugated to standard fluorophores and verified their compatibility with the Cell DIVE multiplexing workflow.
“Antibody specificity, reproducibility, and instrument compatibility are critical for researchers using spatial biology approaches. Our partnership with Leica Microsystems, and their Cell DIVE instrument, shows how we can work together to ensure efficient, accurate data collection, and empower scientific discoveries,” said Roby Polakiewicz, chief scientific officer at CST.
The agreement with CST brings the total number of antibodies that are validated for the Cell DIVE workflow to more than 370.